Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Washington Trust Advisors Inc.

Washington Trust Advisors Inc. decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 11.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,963 shares of the life sciences company’s stock after selling 666 shares during the quarter. Washington Trust Advisors Inc.’s holdings in Illumina were worth $663,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Bleakley Financial Group LLC purchased a new position in Illumina in the fourth quarter valued at approximately $751,000. Zacks Investment Management purchased a new position in Illumina in the third quarter valued at approximately $2,924,000. Van ECK Associates Corp increased its stake in Illumina by 17.5% in the fourth quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company’s stock valued at $20,347,000 after purchasing an additional 22,718 shares during the last quarter. Strategic Financial Concepts LLC purchased a new position in Illumina in the fourth quarter valued at approximately $1,464,000. Finally, Allworth Financial LP increased its stake in Illumina by 720.7% in the fourth quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company’s stock valued at $1,001,000 after purchasing an additional 6,263 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ILMN has been the topic of several recent analyst reports. HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target on the stock. in a research note on Friday, February 28th. Stephens raised their target price on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Hsbc Global Res lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. Barclays lowered shares of Illumina from an “equal weight” rating to an “underweight” rating and lowered their target price for the stock from $130.00 to $100.00 in a research report on Monday, February 10th. Finally, Morgan Stanley lowered their target price on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $149.25.

Illumina Price Performance

Illumina stock opened at $85.69 on Thursday. Illumina, Inc. has a one year low of $80.18 and a one year high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The business has a fifty day moving average of $120.36 and a two-hundred day moving average of $132.17. The company has a market cap of $13.57 billion, a P/E ratio of -11.16, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.